Prognostic and survival analyses of early-stage diffuse large B-cell lymphoma of Waldeyer′s ring

中华放射肿瘤学杂志 Pub Date : 2019-12-15 DOI:10.3760/CMA.J.ISSN.1004-4221.2019.12.004

Huan Li, Tao Wu, Qi-chang Lin, Jing Zhang, Yunfei Hu, Mengxiang Chen, Yunhong Huang

{"title":"Prognostic and survival analyses of early-stage diffuse large B-cell lymphoma of Waldeyer′s ring","authors":"Huan Li, Tao Wu, Qi-chang Lin, Jing Zhang, Yunfei Hu, Mengxiang Chen, Yunhong Huang","doi":"10.3760/CMA.J.ISSN.1004-4221.2019.12.004","DOIUrl":null,"url":null,"abstract":"Objective \nTo analyze the clinical efficacy and prognostic factors of patients with early-stage diffuse large B-cell lymphoma of Waldeyer′s ring (WR-DLBCL) treated with CHOP-based chemotherapy. \n \n \nMethods \nA total of 137 patients diagnosed with WR-DLBCL admitted to our hospitalfrom 2006 to 2018 were enrolled, including 22 patients with stage Ⅰ and 115 patients with stage Ⅱ WR-DLBCL. All patients received CHOP-based chemotherapy, of whom 62 receiving rituximab and 87 receiving involved-field radiotherapy. The overall survival (OS), progression-free survival (PFS) and local recurrence-free survival (LRRFS) were calculated by Kaplan-Meier method. Log-rank test, was conducted for univariate analysis and Cox’s regression model was performed for multivariate analysis. \n \n \nResults \nThe 5-year OS, PFS, and LRFFS in the whole group were 78.6%, 69.5% and 83.2%, and 87.5%, 80.2%, 90.9% in the comprehensive treatment group, and 64.2%, 53.6% 72.9% in the chemotherapy group, respectively. Univariate analysis showed that lactate dehydrogenase (LDH), international prognostic index score, large mass, rituximab, chemotherapy cycle and comprehensive treatment were the prognostic factors of OS and PFS. In addition, LDH, large mass and comprehensive treatment were the prognostic factors associated with LRFFS. Multivariate analysis demonstrated that LDH, comprehensive treatment mode and rituximab were the prognostic factors of OS. LDH and comprehensive treatment mode were the prognostic factors associated with PFS. LDH was a prognostic factor of LRFFS. \n \n \nConclusion \nPatients with early-stage WR-BLBCL obtain excellent clinical prognosis. In the era of rituximab treatment, chemotherapy combined with radiotherapy remains an efficacious treatment of early-stage WR-BLBCL. \n \n \nKey words: \nDiffuse large B-cell lymphoma of Waldeyer′s ring/targeted therapy; Diffuse large B-cell lymphoma of Waldeyer′s ring/radiotherapy; Diffuse large B-cell lymphoma of Waldeyer′s ring/chemotherapy; Prognosis","PeriodicalId":10288,"journal":{"name":"中华放射肿瘤学杂志","volume":"28 1","pages":"896-900"},"PeriodicalIF":0.0000,"publicationDate":"2019-12-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"中华放射肿瘤学杂志","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3760/CMA.J.ISSN.1004-4221.2019.12.004","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

Abstract

Objective To analyze the clinical efficacy and prognostic factors of patients with early-stage diffuse large B-cell lymphoma of Waldeyer′s ring (WR-DLBCL) treated with CHOP-based chemotherapy. Methods A total of 137 patients diagnosed with WR-DLBCL admitted to our hospitalfrom 2006 to 2018 were enrolled, including 22 patients with stage Ⅰ and 115 patients with stage Ⅱ WR-DLBCL. All patients received CHOP-based chemotherapy, of whom 62 receiving rituximab and 87 receiving involved-field radiotherapy. The overall survival (OS), progression-free survival (PFS) and local recurrence-free survival (LRRFS) were calculated by Kaplan-Meier method. Log-rank test, was conducted for univariate analysis and Cox’s regression model was performed for multivariate analysis. Results The 5-year OS, PFS, and LRFFS in the whole group were 78.6%, 69.5% and 83.2%, and 87.5%, 80.2%, 90.9% in the comprehensive treatment group, and 64.2%, 53.6% 72.9% in the chemotherapy group, respectively. Univariate analysis showed that lactate dehydrogenase (LDH), international prognostic index score, large mass, rituximab, chemotherapy cycle and comprehensive treatment were the prognostic factors of OS and PFS. In addition, LDH, large mass and comprehensive treatment were the prognostic factors associated with LRFFS. Multivariate analysis demonstrated that LDH, comprehensive treatment mode and rituximab were the prognostic factors of OS. LDH and comprehensive treatment mode were the prognostic factors associated with PFS. LDH was a prognostic factor of LRFFS. Conclusion Patients with early-stage WR-BLBCL obtain excellent clinical prognosis. In the era of rituximab treatment, chemotherapy combined with radiotherapy remains an efficacious treatment of early-stage WR-BLBCL. Key words: Diffuse large B-cell lymphoma of Waldeyer′s ring/targeted therapy; Diffuse large B-cell lymphoma of Waldeyer′s ring/radiotherapy; Diffuse large B-cell lymphoma of Waldeyer′s ring/chemotherapy; Prognosis

查看原文本刊更多论文

早期弥漫性Waldeyer环大B细胞淋巴瘤的预后和生存率分析

目的分析以CHOP为基础的化疗治疗早期弥漫性Waldeyer环大B细胞淋巴瘤（WR-DLBCL）的临床疗效及影响预后的因素。方法纳入我院2006～2018年收治的137例WR-DLBCL患者，其中Ⅰ期22例，Ⅱ期115例。所有患者均接受基于CHOP的化疗，其中62例接受利妥昔单抗治疗，87例接受现场放疗。采用Kaplan-Meier法计算总生存率（OS）、无进展生存率（PFS）和局部无复发生存率（LRRFS）。对数秩检验用于单变量分析，Cox回归模型用于多变量分析。结果全组5年OS、PFS和LRFFS分别为78.6%、69.5%和83.2%，综合治疗组分别为87.5%、80.2%和90.9%，化疗组分别为64.2%、53.6%和72.9%。单因素分析显示，乳酸脱氢酶（LDH）、国际预后指数评分、大肿块、利妥昔单抗、化疗周期和综合治疗是OS和PFS的预后因素。此外，LDH、大面积和综合治疗是LRFFS的预后因素。多因素分析表明LDH、综合治疗方式和利妥昔单抗是OS的预后因素。LDH和综合治疗方式是影响PFS的预后因素。LDH是LRFFS的预后因素。结论早期WR-BLBCL患者临床预后良好。在利妥昔单抗治疗的时代，化疗结合放疗仍然是早期WR-BLBCL的有效治疗方法。关键词：瓦尔德耶环形弥漫性大B细胞淋巴瘤/靶向治疗；Waldeyer环弥漫性大B细胞淋巴瘤/放射治疗；Waldeyer环弥漫性大B细胞淋巴瘤/化疗；预后

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

中华放射肿瘤学杂志

自引率

0.00%

发文量

6375

期刊介绍： The Chinese Journal of Radiation Oncology is a national academic journal sponsored by the Chinese Medical Association. It was founded in 1992 and the title was written by Chen Minzhang, the former Minister of Health. Its predecessor was the Chinese Journal of Radiation Oncology, which was founded in 1987. The journal is an authoritative journal in the field of radiation oncology in my country. It focuses on clinical tumor radiotherapy, tumor radiation physics, tumor radiation biology, and thermal therapy. Its main readers are middle and senior clinical doctors and scientific researchers. It is now a monthly journal with a large 16-page format and 80 pages of text. For many years, it has adhered to the principle of combining theory with practice and combining improvement with popularization. It now has columns such as monographs, head and neck tumors (monographs), chest tumors (monographs), abdominal tumors (monographs), physics, technology, biology (monographs), reviews, and investigations and research.